Interferon induction by poly (I): poly (C) enclosed in phospholipid particles.
Liposomes were prepared with phospholipids (sphingomyelin, lecithin, and phosphatidylethanolamine) in combination with cholesterol and charged lipids (dicetyl phosphate and stearylamine) and contained either poly(I):poly(C) or poly(I). Neutral and positively charged liposomes attached much better to L-929 cells in tissue culture than did negatively charged particles. Liposomes were toxic to L cells at relatively low concentrations, making the determination of antiviral activity induced by particles containing poly(I):poly(C) difficult to measure by the plaque reduction assay. When injected into mice, all of the liposomes containing poly(I):poly(C), except phosphatidylethanolamine liposomes, greatly potentiated and extended the serum interferon response of poly(I):poly(C). Lecithin and sphingomyelin liposomes given intravenously were ten times more effective than free poly(I):poly(C) in stimulating production of serum interferon. Sphingomyelin liposomes containing [(14)C]poly(I):poly(C) were 88% cleared from the bloodstream of mice by 3 min after intravenous injection. Most of the radioactivity (70%) was captured by the liver and remained there for at least 4 h. By 2 h, 7% of the radioactivity could be found in the spleen. Five percent of the radioactivity was found in the lungs at 30 min, with decreasing amounts thereafter. Small amounts of radioactivity were found in the muscle and kidneys. The spleen was shown to contain appreciable levels of interferon at 4 h, and low levels were found in the liver. Radioactivity accumulated slowly in the liver following an intraperitoneal injection of sphingomyelin liposomes containing [(14)C]poly(I):poly(C). By 4 h, 26% of the dose was recovered from the liver and 4.9% from the spleen, with small amounts in the lung, kidney, and omentum.
D000818:Animals; D001345:Autoradiography; D001682:Biological Availability; D002250:Carbon Radioisotopes; D005260:Female; D007275:Injections, Intravenous; D007372:Interferons / Q000032:analysis; D007739:L Cells; D008081:Liposomes; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D051379:Mice; D010592:Pharmaceutic Aids; D010743:Phospholipids; D011070:Poly I-C / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology; D013154:Spleen / Q000378:metabolism; D014762:Viral Interference / Q000187:drug effects
D002250:Carbon Radioisotopes; D008081:Liposomes; D010592:Pharmaceutic Aids; D010743:Phospholipids; D007372:Interferons; D011070:Poly I-C